Technical Analysis for JAGX - Jaguar Animal Health, Inc.

Grade Last Price % Change Price Change
F 1.06 0.95% 0.01
JAGX closed up 0.95 percent on Friday, November 1, 2024, on 42 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 12
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.95%
Lower Bollinger Band Walk Weakness 0.95%
Down 3 Days in a Row Weakness 0.95%
Lower Bollinger Band Touch Weakness 0.95%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 18 hours ago
Up 1% about 21 hours ago
Fell Below Lower Bollinger Band 2 days ago
Fell Below Previous Day's Low 2 days ago
Down 2 % 2 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Jaguar Animal Health, Inc. Description

Jaguar Animal Health, Inc., a development-stage animal health company, focuses on developing and commercializing gastrointestinal products for companion and production animals. The company's lead prescription drug product candidate includes Canalevia, a canine-specific formulation of Crofelemer for the treatment of CID and general acute watery diarrhea in dogs. It is also developing Crofelemer to treat acute colitis in horses and general acute watery diarrhea in cats; Neonorm, an enteric-coated tablet for scours in preweaned dairy calves, as well as other animal species, such as horses, goats, and sheep; and other product candidates, including Virend and NP-500. The company was founded in 2013 and is headquartered in San Francisco, California. Jaguar Animal Health, Inc. is a subsidiary of Napo Pharmaceuticals, Inc.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Gastrointestinal Animal Health Dog Gastroenterology Prescription Drugs Colitis Drug Products Diarrhea Gastrointestinal Tract Gastrointestinal Products

Is JAGX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Oct 16 Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
Oct 11 Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 10 Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
Oct 9 Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ...
Oct 8 Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial
Oct 2 Jaguar’s diarrhoea drug shows benefit in Phase III breast cancer subgroup
Oct 1 Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
Sep 26 Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients ...
Sep 25 Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
Sep 24 Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch
See more JAGX news...

Indicators

Indicator Value
52 Week High 30.864
52 Week Low 0.9501
Average Volume 245,984
200-Day Moving Average 4.59
50-Day Moving Average 1.17
20-Day Moving Average 1.18
10-Day Moving Average 1.11
Average True Range 0.07
RSI (14) 35.48
ADX 17.17
+DI 16.39
-DI 20.50
Chandelier Exit (Long, 3 ATRs) 1.19
Chandelier Exit (Short, 3 ATRs) 1.23
Upper Bollinger Bands 1.34
Lower Bollinger Band 1.02
Percent B (%b) 0.13
BandWidth 27.16
MACD Line -0.05
MACD Signal Line -0.03
MACD Histogram -0.0134
Fundamentals Value
Market Cap 53.8 Million
Num Shares 50.8 Million
EPS -0.87
Price-to-Earnings (P/E) Ratio -1.22
Price-to-Sales 0.46
Price-to-Book 3.12
PEG Ratio -0.02
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.09
Resistance 3 (R3) 1.09 1.08 1.09
Resistance 2 (R2) 1.08 1.07 1.08 1.08
Resistance 1 (R1) 1.07 1.07 1.07 1.07 1.08
Pivot Point 1.06 1.06 1.06 1.06 1.06
Support 1 (S1) 1.05 1.05 1.05 1.05 1.04
Support 2 (S2) 1.04 1.05 1.04 1.04
Support 3 (S3) 1.03 1.04 1.04
Support 4 (S4) 1.03